This database contains 350 studies, archived under the term: "therapeutic use"
Click here to filter this large number of results.
New insights into clinical trial for Colostrinin in Alzheimer’s disease
Szaniszlo, P.,
German, P.,
Hajas, G.,
Saenz, D. N.,
Kruzel, M.,
Boldogh, I.
Background: The pathomechanism of Alzheimer’s disease (AD) is multifactorial although the most popular hypotheses are centered on the effects of the misfolded, aggregated protein, amyloid beta (Abeta) and on Tau hyperphosphorylation.; Objectives: Double blinded clinical trials were planned to demonstrate the effect of Colostrinin (CLN) on instrumental daily activities of AD patients. The potential molecular […]
Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins
Squitieri, Ferdinando,
Orobello, Sara,
Cannella, Milena,
Martino, Tiziana,
Romanelli, Pantaleo,
Giovacchini, Giampiero,
Frati, Luigi,
Mansi, Luigi,
Ciarmiello, Andrea
Purpose: Huntington disease (HD) mutation increases gain-of-toxic functions contributing to glutamate-mediated excitotoxicity. Riluzole interferes with glutamatergic neurotransmission, thereby reducing excitotoxicity, enhancing neurite formation in damaged motoneurons and increasing serum concentrations of BDNF, a brain cortex neurotrophin protecting striatal neurons from degeneration.; Methods: We investigated metabolic and volumetric differences in distinct brain areas between 11 riluzole-treated […]
Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia
Sommer, Oskar H.,
Aga, Olav,
Cvancarova, Milada,
Olsen, Inge C.,
Selbaek, Geir,
Engedal, Knut
Background/aims: To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of agitation and aggression in patients with Alzheimer’s disease, vascular dementia or both.; Methods: This is an 8-week, multicenter, randomized, double-blind, placebo-controlled trial carried out independently of the pharmaceutical industry. Changes in the agitation and aggression subscore of the Neuropsychiatric Inventory (NPI) were the […]
Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial
Snitz, Beth E.,
O'Meara, Ellen S.,
Carlson, Michelle C.,
Arnold, Alice M.,
Ives, Diane G.,
Rapp, Stephen R.,
Saxton, Judith,
Lopez, Oscar L.,
Dunn, Leslie O.,
Sink, Kaycee M.,
DeKosky, Steven T.
Context: The herbal product Ginkgo biloba is taken frequently with the intention of improving cognitive health in aging. However, evidence from adequately powered clinical trials is lacking regarding its effect on long-term cognitive functioning.; Objective: To determine whether G. biloba slows the rates of global or domain-specific cognitive decline in older adults.; Design, Setting, and […]
Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer’s disease
Sadowsky, Carl H.,
Dengiz, Alan,
Olin, Jason T.,
Koumaras, Barbara,
Meng, Xiangyi,
Brannan, Stephen
Objective: Evaluate safety and tolerability of switching from donepezil to rivastigmine transdermal patch in patients with mild to moderate Alzheimer’s disease.; Methods: Prospective, parallel-group, open-label study to evaluate immediate or delayed switch from 5-10 mg/day donepezil to 4.6 mg/24 h rivastigmine following a 4-week treatment period.; Results: Rates of discontinuation due to any reason or […]
Vascular care in patients with Alzheimer’s disease with cerebrovascular lesions-a randomized clinical trial
Objectives: To investigate whether vascular care slows dementia progression in patients with Alzheimer’s disease with cerebrovascular lesions on neuroimaging.; Design: Multicenter randomized controlled clinical trial with 2-year follow-up.; Setting: Neurological and geriatric outpatient clinics in 10 Dutch hospitals: three academic, five teaching, and two midsize community hospitals.; Participants: One hundred thirty community-dwelling patients with mild […]